About Dr. Woo Cheal Cho
I am an Assistant Professor in the Department of Pathology at MD Anderson Cancer Center. I am board certified in Anatomic and Clinical Pathology with subspecialty board certification in Dermatopathology. I have special academic interests in development of new biomarkers that are not only practically useful in routine Dermatopathology practice but also have potential prognostic value in various cutaneous neoplasms. My current two main research focuses are: 1) to discover new, diagnostically useful, immunohistochemical biomarkers that will enhance diagnostic accuracy of various cutaneous neoplastic and non-neoplastic entities encountered during routine practice and 2) to investigate the genetic (e.g., TERT promoter mutations, TERT gene amplifications and rearrangements) and epigenetic (e.g., TERT promoter hypermethylation) alternations of TERT in rare cutaneous melanocytic tumors, such as spitzoid and blue nevus-like melanomas.
|2022||Division of Pathology and Laboratory Medicine Research Symposium Clinical Poster Presentation Award (1st place, Dr. Kaitlin Vanderbeck), Principal Investigator/Research Mentor, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center|
|2021||Divisional Research Award, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center|
|2021||Chairman’s Fund for Mentored Trainee Research, The University of Texas MD Anderson Cancer Center|
|2020||The Pathologist Power List 2020, The Pathologist magazine|
|2019||Ronald S. Beckett MD Book Award, Department of Pathology and Laboratory Medicine, Hartford Hospital|
|2018||Residents Forum Photography Contest Winner (1st place), College of American Pathologists 2018 Annual Meeting|
|2018||Ludwig J. Pyrtek MD Research Paper Distinction Award, University of Connecticut/Hartford Hospital|
|2016||Excellence in Dermatopathology Award, Department of Pathology and Laboratory Medicine, Hartford Hospital|
- Cho WC, Ding Q, Wang WL, Nagarajan P, Curry JL, Torres-Cabala CA, Ivan D, Albarracin C, Sahin A, Prieto VG, Aung PP. TRPS1 Expression is Frequently Seen in Mammary and Extramammary Paget Diseases, Except for Those Arising in the Perianal Skin. Laboratory Investigation 102((suppl 1)):321-322, 2022.
- Nagarajan P, Gleber-Netto F, Parra E, Pickering C, Davies M, Aung PP, Cho WC, Torres-Cabala CA, Curry JL, Ivan D, Prieto VG, Pettaway C. Exploratory Analyses of Tumor-Infiltrating Inflammatory Cells in Male Genitourinary Melanoma. Laboratory Investigation 102((suppl 1)):344-345, 2022.
- Aung PP, Gill P, Lai Z, Zhu K, Vasudevaraja V, Ivan D, Nagarajan P, Cho WC, Ballester L, Curry JL, Torres-Cabala CA, Prieto VG, Jour G. Multi-omics Analysis of Digital Papillary Adenocarcinoma Reveals Upregulation of MAGEA4 and Infrequent Zinc Finger Genes Rearrangements. Laboratory Investigation 102((suppl 1)):319-320, 2022.
- Ronen S, Billings S, McNiff J, Torres-Cabala CA, George S, Heberton M, Thomas V, Aung PP, Curry JL, Cho WC, Ivan D, Prieto VG, Nagarajan P. Extramammary Post-Radiation Atypical Vascular Lesions: A Clinicopathologic Study of Eight Cases. Laboratory Investigation 102((suppl 1)):350-351, 2022.
- Lazcano R, Hernandez S, Mehta J, Cho WC, Parra E, Solis Soto L, Casavilca Zambrano S, Castillo M, Castaneda C, Nagarajan P, Curry JL, Wistuba I, Prieto VG, Aung PP, Torres-Cabala CA. PD-L1 Expression by Tumor-Associated Macrophages (TAMs) of M2 Subtype is Associated with Overall Survival in Acral Lentiginous Melanoma of Different Ethnicities. Laboratory Investigation 102((suppl 1)):335-337, 2022.
- Saade R, Cho WC, Nagarajan P, Aung PP, Marques-Piubelli M, Hudgens C, Ledesma D, Nelson K, Heberton M, Ivan D, Zhang M, Torres-Cabala CA, Campbell M, Prieto VG, Wistuba I, Esmaeli B, Curry JL. High Expression of Nectin-4 in a Subset of Adnexal Carcinomas: A Potential Target for Enfortumab Vedotin Therapy. Laboratory Investigation 102((suppl 1)):354-356, 2022.
- Vanderbek K, Milton D, Nagarajan P, Rothrock AT, Wang WL, Curry JL, Torres-Cabala CA, Ivan D, Prieto VG, Aung PP, Cho WC. SOX11 Serves as an Effective Discriminatory Marker, When Used in Conjunction with CK20 and TTF1, for Merkel Cell Carcinoma: A Comparative Analysis of SOX11, CK20, PAX5, and TTF1 Expressions in Merkel Cell Carcinomas and Pulmonary Small Cell Carcinomas (**publication with mentoring role**). Laboratory Investigation 102((suppl 1)):363-365, 2022.